|

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

RECRUITINGSponsored by Barbara Ann Karmanos Cancer Institute
Actively Recruiting
SponsorBarbara Ann Karmanos Cancer Institute
Started2009-09
Est. completion2027-05
Eligibility
Age18 Years – 120 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT00935090

Summary

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Eligibility

Age: 18 Years – 120 YearsHealthy volunteers accepted
DISEASE CHARACTERISTICS:

* Meets one of the following criteria:

  * Histologically confirmed solid tumor or hematologic malignancy
  * Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging

PATIENT CHARACTERISTICS:

* Able to lie still in the PET scanner
* Girth and weight must be suitable to enter the gantry
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

* Not specified

Conditions10

Brain and Central Nervous System TumorsCancerChronic Myeloproliferative DisordersLeukemiaLymphomaLymphoproliferative DisorderMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsUnspecified Adult Solid Tumor, Protocol Specific

Locations1 site

Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Clinical Trials Office - Barbara Ann Karmanos Cancer Institute800-527-6266

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.